EDITORIAL ENGLISH
=================
Hello friends of the network I hope that very well, this
Christmas DERMAGIC EXPRESS brings you the second
chapter of THE
CODES OF LYME DISEASE. In the previous review I said that
some details were missing that I was going to clarify in another
edition that I am preparing and that was titled LYME,
SYPHILIS AND LEPROSY, THE MISSING LINK, but I knew
that the CLASSIFICATION
AND CODES OF LYME were INCOMPLETE, and today I
will put here.
I had said that CODES at the DIGITAL or SOFTWARE level are
based on a classification and that this is done in terms of the clinical
presentation of
the disease and REPORTS,
PUBLICATIONS and SCIENTIFIC
INVESTIGATIONS; and that the World Health
Organization (WHO) is TOTALLY
out of date regarding this and THEREFORE there is
not enough coverage of the LYME
DISEASE AND ITS MULTIPLE CLINICAL MANIFESTATIONS,
COMPLICATIONS and SYMPTOMS derived from the permanence of the
SPIROCHETE BORRELIA In the body, the bases that support
these facts are:
1.) DIFFICULTY TO MAKE THE DIAGNOSIS:
2.) RESISTANCE TO CONVENTIONAL TREATMENT:
3.) THE LACK OF MODERNIZATION OF THE CODES FOR THE LYME DISEASE.
And today I bring you other BIBLIOGRAPHIC REFERENCES that
would complete a CLASSIFICATION that in my view would FULLY
ENLARGE assistance to THOUSANDS OF PATIENTS carrying LYME that
simply do not "APPEAR
IN THE SYSTEM" because the CODES do not exist. Today
I add a 4th and 5th aspect:
4.) LYME DISEASE AND HISTOCOMPATIBILITY ANTIGENS: (HLA)
===================================================
It is noteworthy in these data that today I will place, that
the MAJOR
HISTOCOMPATIBILITY SYSTEM (HLA) is HIGHLY involved in the
LYME DISEASE, specifically the patients carrying the HLA
DR molecules, it is even said that the presence of
these molecules or ALLELES are
involved in the pathogenicity of this disease and the
triggering of AUTOIMMUNE
DISEASES. In fact, there are studies showing the RESISTANCE
TO SOME ANTIBIOTICS in relation to these HLA molecules.
There are HLA molecules that confer RESISTANCE TO
THE DISEASE and OTHERS SUSCEPTIBILITY to
the treatment, this would facilitate even more the behavior to
follow with the patients; and I finish with this:
"... ALL PATIENT CARRIER OF LYME HAS TO HAVE A STUDY OF
HISTOCOMPATIBILITY (HLA) ANTIGENS ..."
5.) LYME DISEASE AND GEOGRAPHICAL DISTRIBUTION:
===============================================
It is well known that the BORRELIA
BURGDORFERI and its multiple SPECIES in
the terrestrial globe, ARE DIFFERENT AS TO GEOGRAPHY, both in EUROPE and AMERICA. Well,
I also tell you that there are studies showing that THE
SPECIES OF BORRELIA in
some ZONES such as EUROPE are
sensitive to certain antibiotics, which in other areas of
the continent show resistance, so that the GEOGRAPHICAL
DISTRIBUTION AND SPECIES OF THE
BORRELIA SPIROCHETE must
be included in THE CODES.
6.) LYME DISEASE AND OPTICAL MICROSCOPY:
==========================================
The BORRELIA is
an SPIROCHETE like
the SYPHILIS, and
the METHOD STANDART to detect the SYPHILIS IS OPTICAL
MICROSCOPY, "DARK FIELD", then appeared other more
sophisticated methods such as the VDRL and others. In the
case of the BORRELIA, in the year 2.013 the professors LAANE
and MYSTERUD, invented a simple method based on the fact
that the BORRELIA, like the SYPHILIS
TREPONEMA, could be "DETECTED" by
means of a SIMPLE
OPTICAL MICROSCOPE and that's how it was. They
published the work (ref. 320), but were later discredited and
dismissed by the scientific society including the CDC, claiming
that the most effective methods were the laboratory ones, and
today YET, many
of the tests for LYME are
negative and the BORRELIA
"NAVIGATE" in the blood of patients. There I leave
you the photo of BORRELIA AND BIOFILM and Professor LAANE.
If you read the previous review the CLASSIFICATION had
been in the point No. 15: and here I put the continuation,
it is important that you read the previous revision so that you
can understand: THE
CODES OF THE LYME DISEASE. CLICK
here
15.) LYME LATENT DISEASE: UNSPECIFIED
SYMPTOMS.
A.) INFECTION OF THE CENTRAL NERVOUS SYSTEM.
B.) HERPES SIMPLEX TYPE 1.
C.) DISEASES BY SPIROCHETES OF THE CENTRAL NERVOUS SYSTEM.
--- CONTINUATION--
16.) LYME DISEASE LATE STAGE: SYNDROME
POST TREATMENT (PTLDS):
A.) FATIGUE.
B.) ARTHRALGIA.
C.) FIBROMYALGIA, MYALGIA.
D.) RADICULAR PAIN.
E.) MUSCULOSKELETAL PAIN.
F.) COGNITIVE DYSFUNTICON:
- DECREASED MEMORY.
- CONCETRATION PROBLEMS.
G.) PSYCHIATRICS CONDITIONS:
- DEPRESSION.
- SUICIDAL IDEATION.
- DEMENTIA.
H.) FACIAL PALSY.
I.) AUTOIMMUNE DISORDERS.
17.) LYME DISEASE ASSOCIATED TO OTHER DISEASES:
A.) MULTIPLE SCLEROSIS.
B.) PARKINSON.
C.) AUTOINMMUNE DISORDERS:
- REUMATOID ARTHRITIS.
- PSORIRIATIC ARTHRITIS.
- PERIPHERAL SPONDYLOARTHRITIS.
- POLYARTHRITIS.
18.) LYME DISEASE AND HLA (MAJOR SYSTEM OF HISTOCOMPATIBILITY) TRIGGER
OTHER DISEASES:
A.) LYME ARTHRITIS: HLA-DRB1, (DRB1*0401, 0101, 0404, 0405,
DRB5*0101, DRB1*0402, and 0102), DR11, DR4
19.) LYME DISEASE AND HLA DRB ANTIGENS (MAJOR SYSTEM OF
HISTOCOMPATIBILITY) IS
A MARKER FOR ANTIBIOTIC- REFRACTORY TRATMENT- and
migth play a role in the pathogenesis os the disease.
A.) LYME ARTHRITIS.
20.) LYME DISEASE GEOGRAPHIC DISYTIBUTIONS, SPECIES OF BORRELIA LEADS
TO ANTIBIOTICS
SUSCESPTIBILITY.
A.) EUROPEAN LYME NEUROBORRELIOSIS: SUSCEPTIBILITY TO
DOXYCYCLINE, PENICILLIN G, CEFTRIAXONE AND CEFOTAXIME.
21.) LYME DISEASE EARLY AND DELAYED JARISCH -HERXHEIMER REACCTION
TO ANTIBIOTICS
A.) AMOXICILIN.
B.) DOXYCYCLINE.
C.) CEFTRIAXONE
22.) LYME DISEASE, SECUNDARY OR LATE STAGE: RESISTANT
TO ANTIBIOTICS,
A.) DOXYCYCLINE.
B.) MINOCYCLINE.
C.) CEFTRIAXONE.
D.) AMOXICILIN.
E.) MITOMYCIN C.
F.) CEFUROXIME.
G.) DOXORUBICIN.
23.) LYME DISEASE AND NATURIST HERBS: oregano,
cinnamon bark, and clove improve the disease.
24.) LYME DISEASE SUSCEPIBILITY TO COMBINED ANTIBIOTICS:
A.) DAPSONE + MINOCYCLINE+ CEFUROXIME+ AZYTHROMYCIN
B.)
DAPSONE + MINOCYCLINE+ CEFUROXIME+ RIFAMPICIN
C.) DAPTOMYCIN + DOXYCYCLINE+ CEFUROXIME
D.) DAUNOMYCIN + DOXYCYLINE + CEFUROXIME
E.) DAPTOMYCIN+
CEFOPERAZONE+ DOXYCYCLINE.
F.) DAPTOMYCIN+ DOXYCYCLINE+ CLOFAZIMINE
G.) DATPOMICYN +
(CEFOPERAZONE OR CARBENICILLIN)+ CLOFAZIMINE
I will remind you that the I will remind you that the options DAPSONE + MINOCYCLINE + RIFAMPICIN and DAPSONE + CLOFAZIMINE + RIFAMPICIN are
today classic treatments used in LEPROSY for
more than 60 years and through which they have managed to
reduce the incidence of this disease in the world today.
Practically the arrival of this TRIAD = DAPSONE + RIFAMPICIN + CLOFAZIMINE, in
the 40s -50s years was the one who decreed the FINAL CLOSURE
of the LEPROSERIES in the WORLD, read the stories here:
-
THE LEPROSY IN CAPE WHITE. Clik
Here
-
LEPROSY ON THE ISLAND OF PROVIDENCIA. Click
here
And as I told you before, do not miss the next issue of LYME,
SYPHILIS AND LEPROSY, THE MISSING LINK.
Finally, I would like all the organizations and communities that
fight against the LYME DISEASE, to send this CLASSIFICATION, CODES and BIBLIOGRAPHICAL
REFERENCES to the World Health Organization (WHO), so
that they can be updated regarding the serious problem that this
disease represents in all the PLANET and
that has been neglected for
being aware of other health problems, much smaller, thinking
perhaps that everything related to the word LYME, is
an optical illusion that blinds them to such a severe problem.
Greetings to all.
Dr Jose Lapenta
"... Dedicated to all those LYME
CARRIERS that society has forgotten ...or are in the
oblivion..."
EDITORIAL ESPAÑOL
=================
Hello friends of the network I hope that very well,
this Christmas DERMAGIC EXPRESS brings you the second
chapter of THE
CODES OF LYME DISEASE. In the previous review I said
that some details were missing that I was going to
clarify in another edition that I am preparing and that
was titled LYME,
SYPHILIS AND LEPROSY, THE MISSING LINK, but I
knew that the CLASSIFICATION
AND CODES OF LYME were INCOMPLETE, and
today I will put here.
I had said that CODES at the DIGITAL or SOFTWARE
level are based on a classification and that this is
done in terms of the clinical
presentation of
the disease and REPORTS,
PUBLICATIONS and SCIENTIFIC
INVESTIGATIONS; and that the World Health
Organization (WHO) is TOTALLY
out of date regarding this and THEREFORE there
is not enough coverage of the LYME
DISEASE AND ITS MULTIPLE CLINICAL
MANIFESTATIONS, COMPLICATIONS and SYMPTOMS derived from the
permanence of the SPIROCHETE BORRELIA In the body,
the bases that support these facts are:
1.) DIFFICULTY TO MAKE THE DIAGNOSIS:
2.) RESISTANCE TO CONVENTIONAL TREATMENT:
3.) THE LACK OF MODERNIZATION OF THE CODES FOR THE LYME
DISEASE.
And today I bring you other BIBLIOGRAPHIC REFERENCES that
would complete a CLASSIFICATION that in my view would FULLY
ENLARGE assistance to THOUSANDS OF PATIENTS carrying
LYME that simply do not "APPEAR
IN THE SYSTEM" because the CODES do not
exist. Today I add a 4th and 5th aspect:
4.) LYME DISEASE AND HISTOCOMPATIBILITY ANTIGENS: (HLA)
===================================================
It is noteworthy in these data that today I will place,
that the MAJOR
HISTOCOMPATIBILITY SYSTEM (HLA) is HIGHLY
involved in the LYME DISEASE, specifically the
patients carrying the HLA
DR molecules, it is even said that the
presence of these molecules or ALLELES are
involved in the pathogenicity of this disease and
the triggering of AUTOIMMUNE
DISEASES. In fact, there are studies showing
the RESISTANCE TO SOME ANTIBIOTICS in relation to
these HLA molecules.
There are HLA molecules that confer RESISTANCE TO
THE DISEASE and OTHERS SUSCEPTIBILITY to
the treatment, this would facilitate even more the
behavior to follow with the patients; and I finish with
this:
"... ALL PATIENT CARRIER OF LYME HAS TO HAVE A STUDY OF
HISTOCOMPATIBILITY (HLA) ANTIGENS ..."
5.) LYME DISEASE AND GEOGRAPHICAL DISTRIBUTION:
===============================================
It is well known that the BORRELIA
BURGDORFERI and its multiple SPECIES in
the terrestrial globe, ARE DIFFERENT AS TO GEOGRAPHY,
both in EUROPE and AMERICA. Well,
I also tell you that there are studies showing that THE
SPECIES OF BORRELIA in
some ZONES such as EUROPE are
sensitive to certain antibiotics, which in other
areas of the continent show resistance, so that the GEOGRAPHICAL
DISTRIBUTION AND SPECIES OF THE
BORRELIA SPIROCHETE must
be included in THE CODES.
6.) LYME DISEASE AND OPTICAL MICROSCOPY:
==========================================
The BORRELIA is
an SPIROCHETE like
the SYPHILIS, and
the METHOD STANDART to detect the SYPHILIS IS OPTICAL
MICROSCOPY, "DARK FIELD", then appeared other
more sophisticated methods such as the VDRL and
others. In the case of the BORRELIA, in the year
2.013 the professors LAANE and MYSTERUD, invented a
simple method based on the fact that the BORRELIA,
like the SYPHILIS
TREPONEMA, could be "DETECTED" by
means of a SIMPLE
OPTICAL MICROSCOPE and that's how it was.
They published the work (ref. 320), but were later
discredited and dismissed by the scientific society
including the CDC, claiming that the most effective
methods were the laboratory ones, and today YET, many
of the tests for LYME are
negative and the BORRELIA
"NAVIGATE" in the blood of patients. There I
leave you the photo of BORRELIA AND BIOFILM and
Professor LAANE.
If you read the previous review the CLASSIFICATION had
been in the point No. 15: and here I put the
continuation, it is important that you read the previous
revision so that you can understand: THE
CODES OF THE LYME DISEASE. CLICK
here
15.) LYME LATENT DISEASE: UNSPECIFIED
SYMPTOMS.
A.) INFECTION OF THE CENTRAL NERVOUS SYSTEM.
B.) HERPES SIMPLEX TYPE 1.
C.) DISEASES BY SPIROCHETES OF THE CENTRAL NERVOUS
SYSTEM.
--- CONTINUATION--
16.) LYME DISEASE LATE STAGE: SYNDROME
POST TREATMENT (PTLDS):
A.) FATIGUE.
B.) ARTHRALGIA.
C.) FIBROMYALGIA, MYALGIA.
D.) RADICULAR PAIN.
E.) MUSCULOSKELETAL PAIN.
F.) COGNITIVE DYSFUNTICON:
- DECREASED MEMORY.
- CONCETRATION PROBLEMS.
G.) PSYCHIATRICS CONDITIONS:
- DEPRESSION.
- SUICIDAL IDEATION.
- DEMENTIA.
H.) FACIAL PALSY.
I.) AUTOIMMUNE DISORDERS.
17.) LYME DISEASE ASSOCIATED TO OTHER DISEASES:
A.) MULTIPLE SCLEROSIS.
B.) PARKINSON.
C.) AUTOINMMUNE DISORDERS:
- REUMATOID ARTHRITIS.
- PSORIRIATIC ARTHRITIS.
- PERIPHERAL SPONDYLOARTHRITIS.
- POLYARTHRITIS.
18.) LYME DISEASE AND HLA (MAJOR SYSTEM OF
HISTOCOMPATIBILITY) TRIGGER
OTHER DISEASES:
A.) LYME ARTHRITIS: HLA-DRB1, (DRB1*0401, 0101, 0404,
0405, DRB5*0101, DRB1*0402, and 0102), DR11, DR4
19.) LYME DISEASE AND HLA DRB ANTIGENS (MAJOR SYSTEM
OF HISTOCOMPATIBILITY) IS
A MARKER FOR ANTIBIOTIC- REFRACTORY TRATMENT- and
migth play a role in the pathogenesis os the disease.
A.) LYME ARTHRITIS.
20.) LYME DISEASE GEOGRAPHIC DISYTIBUTIONS, SPECIES OF
BORRELIA LEADS
TO ANTIBIOTICS
SUSCESPTIBILITY.
A.) EUROPEAN LYME NEUROBORRELIOSIS: SUSCEPTIBILITY TO
DOXYCYCLINE, PENICILLIN G, CEFTRIAXONE AND CEFOTAXIME.
21.) LYME DISEASE EARLY AND DELAYED JARISCH
-HERXHEIMER REACCTION
TO ANTIBIOTICS
A.) AMOXICILIN.
B.) DOXYCYCLINE.
C.) CEFTRIAXONE
22.) LYME DISEASE, SECUNDARY OR LATE STAGE: RESISTANT
TO ANTIBIOTICS,
A.) DOXYCYCLINE.
B.) MINOCYCLINE.
C.) CEFTRIAXONE.
D.) AMOXICILIN.
E.) MITOMYCIN C.
F.) CEFUROXIME.
G.) DOXORUBICIN.
23.) LYME DISEASE AND NATURIST HERBS: oregano,
cinnamon bark, and clove improve the disease.
24.) LYME DISEASE SUSCEPIBILITY TO COMBINED ANTIBIOTICS:
A.) DAPSONE + MINOCYCLINE+ CEFUROXIME+ AZYTHROMYCIN
B.)
DAPSONE + MINOCYCLINE+ CEFUROXIME+ RIFAMPICIN
C.) DAPTOMYCIN + DOXYCYCLINE+ CEFUROXIME
D.) DAUNOMYCIN + DOXYCYLINE + CEFUROXIME
E.) DAPTOMYCIN+
CEFOPERAZONE+ DOXYCYCLINE.
F.) DAPTOMYCIN+ DOXYCYCLINE+ CLOFAZIMINE
G.) DATPOMICYN +
(CEFOPERAZONE OR CARBENICILLIN)+ CLOFAZIMINE
I will remind you that the options DAPSONE + MINOCYCLINE + RIFAMPICIN and DAPSONE + CLOFAZIMINE + RIFAMPICIN are
today classic treatments used in LEPROSY for
more than 60 years and through which they have
managed to reduce the incidence of this disease in
the world today.
Practically the arrival of this TRIAD = DAPSONE + RIFAMPICIN + CLOFAZIMINE, in
the 40s -50s years was the one who decreed the FINAL
CLOSURE of the LEPROSERIES in the WORLD, read the
stories here:
-
THE LEPROSY IN CAPE WHITE. Clik
Here
-
LEPROSY ON THE ISLAND OF PROVIDENCIA. Click
here
And as I told you before, do not miss the next issue of LYME,
SYPHILIS AND LEPROSY, THE MISSING LINK.
Finally, I would like all the organizations and
communities that fight against the LYME DISEASE, to send
this CLASSIFICATION, CODES and BIBLIOGRAPHICAL
REFERENCES to the World Health Organization (WHO),
so that they can be updated regarding the serious
problem that this disease represents in all the PLANET and
that has been neglected for
being aware of other health problems, much smaller,
thinking perhaps that everything related to the word LYME, is
an optical illusion that blinds them to such a severe
problem.
Greetings to all.
Dr Jose Lapenta
"... Dedicated to all those LYME
CARRIERS that society has forgotten ...or are in the
oblivion..."
===========================================================================
EBIBLIGRAPHICAL REFERENCES
/
REFERENCIAS BIBLIOGRAFICAS
===========================================================================
282.) Effects of intravenous ketamine in a patient with post-treatment
Lyme disease syndrome. Int Med Case Rep J. 2017 Aug
18;10:305-308. doi: 10.2147/IMCRJ.S137975. eCollection 2017. [PUBMED]
Hanna AF1, Abraham B1, Hanna A1, Smith AJ1.
283.) Update of the Swiss guidelines on post-treatment Lyme
disease syndrome. Swiss Med Wkly. 2016 Dec 5;146:w14353. doi:
10.4414/smw.2016.14353. eCollection 2016. [PUBMED] Nemeth J1,
Bernasconi E2, Heininger U3, Abbas M4, Nadal D5, Strahm C6, Erb
S7, Zimmerli S8, Furrer H8, Delaloye J9, Kuntzer T10, Altpeter
E11, Sturzenegger M12, Weber R1,
284.) Lyme disease and post-treatment Lyme disease syndrome: the
neglected disease in our own backyard.Public Health. 2014
Sep;128(9):784-91. doi: 10.1016/j.puhe.2014.06.016. Epub 2014
Sep 9. [PUBMED]
285.) Post-Lyme borreliosis syndrome: a meta-analysis of
reported symptoms.Int J Epidemiol. 2005 Dec;34(6):1340-5. Epub
2005 Jul 22. [PUBMED] Cairns V1, Godwin J.
286.) Post-Lyme disease syndrome. Reumatologia.2015;53(1):46-8.doi:
10.5114/ reum. 2015.50557. Epub 2015 Apr 10.[PUBMED] Scieszka
J1, Dabek J2, Cieslik P1.
287.) Comparison of post-Lyme Borreliosis symptoms in erythema
migrans patients with positive and negative Borrelia burgdorferi
sensu lato skin culture.Vector Borne Zoonotic Dis. 2011 Jul;11(7):883-9.
doi: 10.1089/vbz.2010.0018. Epub 2010 Nov 17. [PUBMED] Stupica
D1, Lusa L, Cerar T, Ružic-Sabljic E, Strle F.
288.) Long-term Assessment of Post-Treatment Symptoms in
Patients With Culture-Confirmed Early Lyme Disease. Clin Infect
Dis. 2015 Dec 15;61(12):1800-6. doi: 10.1093/cid/civ735. Epub
2015 Sep 18. [PUBMED] Weitzner E1, McKenna D1, Nowakowski J1,
Scavarda C1, Dornbush R2, Bittker S1, Cooper D1, Nadelman RB1,
Visintainer P3, Schwartz I4, Wormser GP1.
289.) Chronic Lyme borreliosis at the root of multiple sclerosis--is
a cure with antibiotics attainable? Med Hypotheses.
2005;64(3):438-48. [PUBMED] Fritzsche M1.
290.) The Data as It Is, and the Nature of Neurocognitive
Difficulties in Post-Treatment Lyme Disease. Arch Clin
Neuropsychol. 2017 Dec 13. doi: 10.1093/arclin/acx121. [Epub
ahead of print] [PUBMED] Keilp JG1, Fallon BA2.
291.) Clinical and neurocognitive features of the post Lyme
syndrome. J Rheumatol. 1996 Aug;23(8):1392-7. [PUBMED] Bujak
DI1, Weinstein A, Dornbush RL.
292.) Terrestrial distribution of the Lyme borreliosis agent
Borrelia burgdorferi sensu lato in East Asia. Jpn J Infect Dis.
2004 Dec;57(6):229-35. [PUBMED] Masuzawa T1.
293.) Variable manifestations, diverse seroreactivity and post-treatment
persistence in non-human primates exposed to Borrelia
burgdorferi by tick feeding. PLoS One. 2017 Dec
13;12(12):e0189071. doi: 10.1371/journal.pone.0189071.
eCollection 2017. [PUBMED]
Embers ME1, Hasenkampf NR1, Jacobs MB1, Tardo AC1, Doyle-Meyers
LA2, Philipp MT1, Hodzic E3.
294.) Persistence of Borrelia burgdorferi in rhesus macaques
following antibiotic treatment of disseminated infection. PLoS
One. 2012;7(1):e29914. doi: 10.1371/journal.pone.0029914. Epub
2012 Jan 11. [PUBMED] Embers ME1, Barthold SW, Borda JT, Bowers
L, Doyle L, Hodzic E, Jacobs MB, Hasenkampf NR, Martin DS,
Narasimhan S, Phillippi-Falkenstein KM, Purcell JE, Ratterree
MS, Philipp MT.
295.) Unique expression of chronic Lyme disease and Jarisch-Herxheimer
reaction to doxycycline therapy in a young adult. BMJ Case Rep.
2016 Jul 20;2016. pii: bcr2013009433. doi: 10.1136/bcr-2013-009433.
[PUBMED] Haney C1, Nahata MC2.
296.) Lyme disease complicated by the Jarisch-Herxheimer
reaction. J Emerg Med. 1998 May-Jun;16(3):437-8.[PUBMED] Maloy
AL1, Black RD, Segurola RJ Jr.
297.) Delayed onset of the Jarisch-Herxheimer reaction in
doxycycline-treated disease: a case report and review of its
histopathology and implications for pathogenesis. Am J
Dermatopathol. 2015 Jun;37(6):e68-74. doi:
10.1097/DAD.0000000000000093. [PUBMED] Kadam P1, Gregory NA,
Zelger B, Carlson JA.
298.) Transient worsening of optic neuropathy as a sequela of
the Jarisch-Herxheimer reaction in the treatment of Lyme disease.
J Neuroophthalmol. 1994 Jun;14(2):77-80. [PUBMED] Strominger
MB1, Slamovits TL, Herskovitz S, Lipton RB.
299.) Successful desensitisation to ceftriaxone in a patient
with doxycicline resistant Lyme disease. Erratum in Allergol
Immunopathol (Madr). 2009 Jul-Aug;37(4):222.[PUBMED] Rodrigues
J, Cruz LG, Botelho C, Rio E, Castel-Branco MG.
300.) Ceftriaxone Pulse Dosing Fails to Eradicate Biofilm-Like
Microcolony B. burgdorferi Persisters Which Are Sterilized by
Daptomycin/ Doxycycline/Cefuroxime without Pulse Dosing. Front
Microbiol. 2016 Nov 4;7:1744. eCollection 2016. [PUBMED] Feng
J1, Zhang S1, Shi W1, Zhang Y1.
301.) Antibiotics for the neurological complications of Lyme
disease. Cochrane Database Syst Rev. 2016 Dec 8;12:CD006978. doi:
10.1002/14651858.CD006978.pub2. [PUBMED] Cadavid D1, Auwaerter
PG2, Rumbaugh J3, Gelderblom H4.
302.) Lyme borreliosis in Slovenia. Zentralbl Bakteriol. 1999
Dec;289(5-7):643-52. [PUBMED] Strle F1.
303.) Immunogenic HLA-DR-Presented Self-Peptides Identified
Directly from Clinical Samples of Synovial Tissue, Synovial
Fluid, or Peripheral Blood in Patients with Rheumatoid Arthritis
or Lyme Arthritis. J Proteome Res. 2017 Jan 6;16(1):122-136. doi:
10.1021/acs.jproteome.6b00386. Epub 2016 Nov 7. [PUBMED] Wang
Q1, Drouin EE2, Yao C1, Zhang J1,3, Huang Y1, Leon DR1, Steere
AC2, Costello CE1.
304.) Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic
Arthritis, or Peripheral Spondyloarthritis Following Lyme
Disease. Arthritis Rheumatol. 2017 Jan;69(1):194-202. doi:
10.1002/art.39866. [PUBMED] Arvikar SL1, Crowley JT1, Sulka KB1,
Steere AC1.
305.) T-Helper 17 Cell Cytokine Responses in Lyme Disease
Correlate With Borrelia burgdorferi Antibodies During Early
Infection and With Autoantibodies Late in the Illness in
Patients With Antibiotic-Refractory Lyme Arthritis. Clin Infect
Dis. 2017 Apr 1;64(7):930-938. doi: 10.1093/cid/cix002. [PUBMED]
Strle K1, Sulka KB1, Pianta A1, Crowley JT1, Arvikar SL1,
Anselmo A2, Sadreyev R2, Steere AC1.
306.) Serum reactivity against Borrelia burgdorferi OspA in
patients with rheumatoid arthritis. Clin Vaccine Immunol. 2007
Nov;14(11):1437-41. Epub 2007 Sep 19. [PUBMED] Hsieh YF1, Liu HW,
Hsu TC, Wei JC, Shih CM, Krause PJ, Tsay GJ.
307.) HLA type and immune response to Borrelia burgdorferi outer
surface protein a in people in
whom arthritis developed after Lyme disease vaccination.
Arthritis Rheum. 2009 Apr;60(4):1179-86. doi: 10.1002/art.24418.[PUBMED]Ball
R1, Shadomy SV, Meyer A, Huber BT, Leffell MS, Zachary A,
Belotto M, Hilton E, Bryant-Genevier M, Schriefer ME, Miller FW,
Braun MM.
308.) HLA-DR alleles determine responsiveness to Borrelia
burgdorferi antigens in a mouse model of self-perpetuating
arthritis. Arthritis Rheum. 2009 Dec;60(12):3831-40. doi:
10.1002/art.25005. [PUBMED] Iliopoulou BP1, Guerau-de-Arellano
M, Huber BT.
309.) Antibiotic-refractory Lyme arthritis is associated with
HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp
Med. 2006 Apr 17;203(4):961-71. Epub 2006 Apr 3. [PUBMED] Steere
AC1, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT, Baxter-Lowe
LA.
310.) Association of antibiotic treatment-resistant Lyme
arthritis with T cell responses to dominant epitopes of outer
surface protein A of Borrelia burgdorferi. Arthritis Rheum. 1999
Sep;42(9):1813-22. [PUBMED] Chen J1, Field JA, Glickstein L,
Molloy PJ, Huber BT, Steere AC.
311.) Associations of HLA DR and DQ molecules with Lyme
borreliosis in Latvian patients. BMC Res Notes. 2012 Aug
14;5:438. doi: 10.1186/1756-0500-5-438. [PUBMED] Kovalchuka L1,
Eglite J, Lucenko I, Zalite M, Viksna L, Krumina A.
312.) Immunogenetic Markers Definition in Latvian Patients with
Lyme Borreliosis and Lyme Neuroborreliosis. Int J Environ Res
Public Health. 2016 Dec 1;13(12). pii: E1194. [PUBMED]
Kovalchuka L1, Cvetkova S2, Trofimova J3, Eglite J4, Gintere S5,
Lucenko I6, Oczko-Grzesik B7, Viksna L8, Krumina A9,10.
313.) Serological Evidence of Borrelia Burgdorferi Infection in
Mexican Patients with Facial Palsy. Rev Invest Clin. 2017 Nov-Dec;69(6):344-348.
doi: 10.24875/RIC.17002344. [PUBMED] Gordillo-Pérez G1,
García-Juárez I1, Solórzano-Santos F2, Corrales-Zúñiga L3,
Muñoz-Hernández O2, Torres-López J1.
314.) Selective Essential Oils from Spice or Culinary Herbs Have
High Activity against Stationary Phase and Biofilm Borrelia
burgdorferi. Front Med (Lausanne). 2017 Oct 11;4:169. doi:
10.3389/fmed.2017.00169. eCollection 2017. [PUBMED] Feng J1,
Zhang S1, Shi W1, Zubcevik N2, Miklossy J3, Zhang Y1.
315.) Eradication of Biofilm-Like Microcolony Structures of
Borrelia burgdorferi by Daunomycin and Daptomycin but not
Mitomycin C in Combination with Doxycycline and Cefuroxime.
Front Microbiol. 2016 Feb 10;7:62. doi: 10.3389/fmicb.2016.00062.
eCollection 2016. [PUBMED] Feng J1, Weitner M1, Shi W1, Zhang
S1, Zhang Y1.
316.) Drug combinations against Borrelia burgdorferi persisters
in vitro: eradication achieved by using daptomycin, cefoperazone
and doxycycline. PLoS One. 2015 Mar 25;10(3):e0117207. doi:
10.1371/journal.pone.0117207. eCollection 2015. [PUBMED] Feng
J1, Auwaerter PG2, Zhang Y1.
317.) Activity of Sulfa Drugs and Their Combinations against
Stationary Phase B. burgdorferi In Vitro. Antibiotics (Basel).
2017 Mar 22;6(1). pii: E10. doi: 10.3390/antibiotics6010010. [PUBMED]
Feng J1, Zhang S2, Shi W3, Zhang Y4.
318.) Lyme neuroborreliosis and dementia. J Alzheimers Dis.
2014;41(4):1087-93. doi: 10.3233/JAD-130446. [PUBMED]Blanc F1,
Philippi N1, Cretin B1, Kleitz C2, Berly L2, Jung B1, Kremer S3,
Namer IJ4, Sellal F5, Jaulhac B6, de Seze J7.
319.) Distribution and presentation of Lyme borreliosis in
Scotland - analysis of data from a national testing laboratory.
J R Coll Physicians Edinb. 2015;45(3):196-200. doi: 10.4997/JRCPE.2015.304.
[PUBMED] Mavin S1, Watson EJ, Evans R.
320.) A simple method for the detection of live Borrelia
spirochaetes in human blood using classical microscopy
techniques. Morten Motzfeldt Laane, Ivar Mysterud. Published
2013. Semantic Sholar. Source: https://www.semanticscholar.org/paper/A-simple-method-for-the-detection-of-live-Borrelia-Laane-Mysterud/4f6251e40f196b094905d84e87b8b6fe8d1d1636
Source: https://madisonarealymesupportgroup.com/
===================================================================